Lexicon Pharmaceuticals

Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Clinical Trials Arena
Lexicon Pharmaceuticals
Inpefa
clinical trials
heart failure
AHA
Flag link:
Lexicon gets FDA approval for Inpefa to treat heart failure
Lexicon gets FDA approval for Inpefa to treat heart failure
Pharmaceutical Technology
Lexicon Pharmaceuticals
FDA
Inpefa
heart failure
Flag link:
Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate
Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate
Endpoints
Lexicon Pharmaceuticals
FDA
type 1 diabetes
sotagliflozin
Flag link:
Lexicon CEO touts ‘wonderful morning’ as diabetic pain drug clears phase 2, teeing up hopeful partnership talks
Lexicon CEO touts ‘wonderful morning’ as diabetic pain drug clears phase 2, teeing up hopeful partnership talks
Fierce Biotech
Lexicon Pharmaceuticals
diabetic neuropathy
diabetes
diabetic pain
clinical trials
LX9211
Flag link:
Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure
Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure
Endpoints
Lexicon Pharmaceuticals
sotagliflozin
heart failure
FDA
Flag link:
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals
Fierce Pharma
Lexicon Pharmaceuticals
ACC
diabetes
sotagliflozin
type 2 diabetes
heart failure
Flag link:
3 Biotech Stocks That Jumped Last Week
3 Biotech Stocks That Jumped Last Week
Motley Fool
biotech
biotech stocks
Lexicon Pharmaceuticals
sotagliflozin
Nucana
Aldeyra Therapeutics
reproxalap
Flag link:
The biotech resurrection continues
The biotech resurrection continues
EP Vantage
biotech
Lexicon Pharmaceuticals
DBV Technologies
Pfizer
Trillium Therapeutics
Flag link:
AHA 2020 – sotagliflozin wins come too late for Lexicon
AHA 2020 – sotagliflozin wins come too late for Lexicon
EP Vantage
Lexicon Pharmaceuticals
sotagliflozin
AHA
heart failure
chronic kidney disease
Flag link:
Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline
Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline
Endpoints
Lexicon Pharmaceuticals
Xermelo
R&D
TerSera Therapeutics
Flag link:
Lexicon Pharma shares plummet after FDA denies appeal against drug rejection
Lexicon Pharma shares plummet after FDA denies appeal against drug rejection
Reuters
Lexicon Pharmaceuticals
FDA
type 1 diabetes
Zynquista
Flag link:
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Yahoo/Benzinga
Merck
Pifeltro
FDA
Delstrigo
Novo Nordisk
oral semaglutide
Kodiak Sciences
MeiraGTx Holdings
IPOs
Exagen
IGM Biosciences
Arrowhead Pharmaceuticals
Lexicon Pharmaceuticals
Bluebird Bio
vTv Therapeutics
Flag link:
Sanofi paying Lexicon $260M to exit diabetes alliance
Sanofi paying Lexicon $260M to exit diabetes alliance
BioPharma Dive
Sanofi
Lexicon Pharmaceuticals
diabetes
type 1 diabetes
Zynquista
Flag link:
Sanofi ends partnership with Lexicon after trial failure
Sanofi ends partnership with Lexicon after trial failure
In-Pharma Technologist
Sanofi
Lexicon Pharmaceuticals
clinical trials
Zynquista
diabetes
Flag link:
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
Flag link:
What's Next for Lexicon Pharmaceuticals?
What's Next for Lexicon Pharmaceuticals?
Motley Fool
Lexicon Pharmaceuticals
sotagliflozin
Zynquista
Sanofi
diabetes
Flag link:
Sanofi, Lexicon get complete response letter for Zynquista
Sanofi, Lexicon get complete response letter for Zynquista
BioCentury
Sanofi
Zynquista
Lexicon Pharmaceuticals
type 1 diabetes
FDA
Flag link:
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
Yahoo/Zacks.com
Lexicon Pharmaceuticals
clinical trials
Xermelo
biliary tract cancer
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
3 Top Diabetes Stocks to Watch in February
3 Top Diabetes Stocks to Watch in February
Motley Fool
diabetes
Zynquista
Lexicon Pharmaceuticals
devices
Tandem Diabetes
insulin pumps
Insulet
Flag link:

Pages